Market Access -

Trending

in News
AZ, MSD’s Koselugo is first EU therapy for neurofibromatosis
June 22, 2021 Share
X
AZ, MSD’s Koselugo is first EU therapy for neurofibromatosis
https://pharmaphorum.com/news/az-msds-koselugo-is-first-eu-therapy-for-neurofibromatosis/
in News
After FDA rejection, EU says yes to Sanofi’s Aubagio in kids with MS
June 21, 2021 Share
X
After FDA rejection, EU says yes to Sanofi’s Aubagio in kids with MS
https://pharmaphorum.com/news/after-fda-rejection-eu-says-yes-to-sanofis-aubagio-in-children/

Latest News

EU okays BMS’ azacitidine pill for first-line maintenance of AML

EU okays BMS’ azacitidine pill for first-line maintenance of AML

Bristol-Myers Squibb has been granted EU approval for Onureg (azacitidine), a tablet form of an intravenous drug that

X

EU okays BMS’ azacitidine pill for first-line maintenance of AML

https://pharmaphorum.com/news/eu-okays-bms-azacitidine-pill-for-first-line-maintenance-of-aml/

NICE backs Novartis’ Cosentyx for underdiagnosed back condition

NICE backs Novartis’ Cosentyx for underdiagnosed back condition

NICE has extended the range of indications that Novartis’ Cosentyx can be prescribed for by the NHS in

X

NICE backs Novartis’ Cosentyx for underdiagnosed back condition

https://pharmaphorum.com/news/nice-backs-novartis-cosentyx-for-underdiagnosed-back-condition/

Blueprint’s latest approval for Ayvakit sets up clash with Novartis

Blueprint’s latest approval for Ayvakit sets up clash with Novartis

Blueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM),

X

Blueprint’s latest approval for Ayvakit sets up clash with Novartis

https://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/

Views & analysis

Building honest dialogue with patient advocates

Building honest dialogue with patient advocates

How can the industry listen to patients in a way that puts the person behind the disease first?

X

Building honest dialogue with patient advocates

https://deep-dive.pharmaphorum.com/magazine/market-access-2021/building-honest-dialogue-with-patient-advocates/

Turning words into actions with patient engagement

Turning words into actions with patient engagement

Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients

X

Turning words into actions with patient engagement

https://deep-dive.pharmaphorum.com/magazine/market-access-2021/turning-words-into-actions-with-patient-engagement-boehringer-ingelheim/

A roadmap for adopting New Science

A roadmap for adopting New Science

The pandemic’s disruption galvanised the biopharma industry into unprecedented action, demonstrating what’s possible when the global scientific community

X

A roadmap for adopting New Science

https://pharmaphorum.com/market-access-2/a-roadmap-for-adopting-new-science/

Debates & Insights

Innovative contracting in Europe – a Trojan horse?

Innovative contracting in Europe – a Trojan horse?

Overview With pricing of drugs at the centre of political and social debate, the market access and pricing

X

Innovative contracting in Europe – a Trojan horse?

https://pharmaphorum.com/market-access-2/innovative-contracting-in-europe-a-trojan-horse/

Launch excellence in a disrupted world – challenges & opportunities

Launch excellence in a disrupted world – challenges & opportunities

Overview The launch environment has undergone huge changes as the pharmaceutical industry’s focus has moved from primary care

X

Launch excellence in a disrupted world – challenges & opportunities

https://pharmaphorum.com/market-access-2/launch-excellence-in-a-disrupted-world-challenges-opportunities/

Orphan medicines launch excellence: sustaining launch success

Orphan medicines launch excellence: sustaining launch success

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients

X

Orphan medicines launch excellence: sustaining launch success

https://pharmaphorum.com/market-access-2/orphan-medicines-launch-excellence-sustaining-launch-success/

Partner Content

Partnerships in pharma: exploring intersections across molecules and software

Partnerships in pharma: exploring intersections across molecules and software

Healthware Labs and Plexus Ventures will host a webinar

X

Partnerships in pharma: exploring intersections across molecules and software

https://pharmaphorum.com/events/partnerships-in-pharma-exploring-intersections-across-molecules-and-software/

RBQM Live: The Definitive Guide to RBQM for Experts and Beginners

RBQM Live: The Definitive Guide to RBQM for Experts and Beginners

RBQM Live two-day virtual event May 20-21

X

RBQM Live: The Definitive Guide to RBQM for Experts and Beginners

https://pharmaphorum.com/events/rbqm-live-the-definitive-guide-to-rbqm-for-experts-and-beginners/

2nd Manufacturing Assets & Facility Management in Pharma (MAFM) Summit

2nd Manufacturing Assets & Facility Management in Pharma (MAFM) Summit

Industry Led Conference on Pharma Manufacturing

X

2nd Manufacturing Assets & Facility Management in Pharma (MAFM) Summit

https://pharmaphorum.com/events/2nd-manufacturing-assets-facility-management-in-pharma-mafm-summit/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com